Scott Schoenhaus
Stock Analyst at Keybanc
(1.15)
# 3,473
Out of 4,711 analysts
79
Total ratings
28.36%
Success rate
-10.31%
Average return
Main Sectors:
Stocks Rated by Scott Schoenhaus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TALK Talkspace | Initiates: Overweight | $4.5 | $2.98 | +51.01% | 1 | Dec 9, 2024 | |
| ALIT Alight | Maintains: Overweight | $10 → $11 | $6.86 | +60.35% | 6 | Nov 13, 2024 | |
| DOCS Doximity | Upgrades: Overweight | $70 | $57.83 | +21.04% | 1 | Nov 8, 2024 | |
| SLP Simulations Plus | Initiates: Overweight | $47 | $28.58 | +64.45% | 1 | Jul 29, 2024 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $7 → $5 | $2.85 | +75.44% | 3 | Jul 11, 2024 | |
| ABSI Absci | Maintains: Overweight | $8 → $6 | $2.99 | +100.67% | 4 | Jul 11, 2024 | |
| CERT Certara | Maintains: Overweight | $23 → $20 | $10.71 | +86.74% | 3 | Jul 11, 2024 | |
| LFMD LifeMD | Maintains: Overweight | $12 → $10 | $5.04 | +98.41% | 2 | Jul 11, 2024 | |
| PHR Phreesia | Maintains: Overweight | $27 → $25 | $25.16 | -0.64% | 5 | Jul 11, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Overweight | $16 → $12 | $6.03 | +99.00% | 5 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $19.44 | +28.60% | 3 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $100 | $94.95 | +5.32% | 3 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $14.34 | - | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $7.09 | - | 4 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 | $4.44 | +102.70% | 4 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $232 → $250 | $224.15 | +11.53% | 14 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $44.98 | - | 8 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $43.76 | +37.11% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Weight | n/a | $9.44 | - | 4 | Sep 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $180 → $250 | $197.27 | +26.73% | 2 | Apr 16, 2021 |
Talkspace
Dec 9, 2024
Initiates: Overweight
Price Target: $4.5
Current: $2.98
Upside: +51.01%
Alight
Nov 13, 2024
Maintains: Overweight
Price Target: $10 → $11
Current: $6.86
Upside: +60.35%
Doximity
Nov 8, 2024
Upgrades: Overweight
Price Target: $70
Current: $57.83
Upside: +21.04%
Simulations Plus
Jul 29, 2024
Initiates: Overweight
Price Target: $47
Current: $28.58
Upside: +64.45%
AbCellera Biologics
Jul 11, 2024
Maintains: Overweight
Price Target: $7 → $5
Current: $2.85
Upside: +75.44%
Absci
Jul 11, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $2.99
Upside: +100.67%
Certara
Jul 11, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $10.71
Upside: +86.74%
LifeMD
Jul 11, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $5.04
Upside: +98.41%
Phreesia
Jul 11, 2024
Maintains: Overweight
Price Target: $27 → $25
Current: $25.16
Upside: -0.64%
Recursion Pharmaceuticals
Jul 11, 2024
Maintains: Overweight
Price Target: $16 → $12
Current: $6.03
Upside: +99.00%
Jul 11, 2024
Maintains: Overweight
Price Target: $30 → $25
Current: $19.44
Upside: +28.60%
Jun 5, 2024
Maintains: Overweight
Price Target: $95 → $100
Current: $94.95
Upside: +5.32%
May 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $14.34
Upside: -
Apr 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $7.09
Upside: -
Apr 10, 2024
Upgrades: Overweight
Price Target: $9
Current: $4.44
Upside: +102.70%
Mar 5, 2024
Maintains: Overweight
Price Target: $232 → $250
Current: $224.15
Upside: +11.53%
Oct 11, 2023
Downgrades: Sector Weight
Price Target: n/a
Current: $44.98
Upside: -
Aug 15, 2023
Initiates: Overweight
Price Target: $60
Current: $43.76
Upside: +37.11%
Sep 16, 2022
Initiates: Sector Weight
Price Target: n/a
Current: $9.44
Upside: -
Apr 16, 2021
Upgrades: Overweight
Price Target: $180 → $250
Current: $197.27
Upside: +26.73%